Biorelevant dissolution of candesartan cilexetil

Preparation of Candesartan Cilexetil Nanoparticles by Precipitation

The ADME of a drug involves its transport across cell membranes. This process is essential and influenced by the characteristics of the drug, especially its molecular size and shape, solubility at the site of its absorption, relative lipid solubility, etc. Over the last ten years, the number of poorly soluble drugs has steadily increased. One of the progressive ways for increasing bioavaibility...

Re: Evaluation of acute candesartan cilexetil therapy in stroke survivors.

Preparation and Characterization of Candesartan Cilexetil Solid Lipid Nanoparticulate Capsules

The candesartan cilexetil belongs to class II of the biopharmaceutical classification system and bioavailability is 15% due to the poor aqueous solubility. The purpose of the study is to improve aqueous solubility by nano technology of solid lipid nanoparticle by solvent evaporation method. Here glyceryl monosterate (lipid), polaxemor 407, tweeen 80 (co-surfactant and surfactant respectively) a...

Candesartan cilexetil in the treatment of chronic heart failure

The prevalence of heart failure is ever increasing around the world, particularly due to aging populations. Despite improvements in treatment over the last 20 years, the prognosis for heart failure remains poor. Among the treatments recommended for chronic heart failure, angiotensin-converting enzyme (ACE) inhibitors and beta-blockers are crucial, provided of course that they are not contraindi...

ATACAND HCT 16-12.5 (candesartan cilexetil−hydrochlorothiazide) TABLETS, FOR ORAL USE ATACAND HCT 32-12.5 (candesartan cilexetil−hydrochlorothiazide) TABLETS, FOR ORAL USE ATACAND HCT 32–25 (candesartan cilexetil-hydrochlorothiazide) TABLETS, FOR ORAL USE WARNING: FETAL TOXICITY